Inicio
Entrar
Ayuda
Buscar en este sitio:
Ensayos Registrados
Por tipo de intervención
Por estado de reclutamiento
Por promotor
Por fecha de registro
Búsqueda avanzada de ensayos
Proceso de Registro
Para registrar un ensayo
Formulario del Promotor
Formulario de ensayos del RPCEC
Para actualizar un ensayo registrado
Para reportar los resultados de un ensayo registrado
Inicio
|
Pharmacodynamics of the Nasalferon in healthy volunteers.
View current
Revisiones
List all revisions
Ver
Compare to current
13 Julio 2020 - 10:56am
por lazara
28 Febrero 2023 - 11:54am
por CIGB
< diferencia anterior
Cambios a
Recruitment status
-
Pending
+
Suspended
Cambios a
Intervention code
-
+
Interferon alpha-2
+
Interferon-alpha
+
Interferons
+
Administration, Sublingual
+
Administration, Intranasal
+
Nasal Sprays
Cambios a
Record Verification Date
-
2020
/
07
/
13
+
2023
/
02
/
28
Cambios a
Next update date
-
2021
/
07
/
13
+
2024
/
02
/
28
Revisión de 28 Febrero 2023 - 11:54am
Pharmacodynamics of the Nasalferon in healthy volunteers.
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Scientific title:
Pharmacodynamics and safety of recombinant interferon alfa 2b, by different routes of administration, in healthy volunteers (COVID-19).
Secondary indentifying numbers:
IG/IAGN/VS/2001
Issuing authority of the secondary identifying numbers:
Center for Genetic Engineering and Biotechnology (CIGB)
Primary sponsor:
Center for Genetic Engineering and Biotechnology (CIGB), in Havana
Secondary sponsor:
Not applicable
Source(s) of monetary or material support:
Center for Genetic Engineering and Biotechnology (CIGB), Havana. Ministry of Public Health, Cuba.
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Center for State Control of Drugs, Medical Devices and Equipment (CECMED)
Reference number:
In process
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Carlos
Midle name:
Alberto
Last name:
Gonzalez Delgado
Medical Specialty :
2nd degree specialist in Clinical Pharmacology
Affiliation:
National Toxicology Center (CENATOX)
Postal address:
Calle 114 y Ave. 31, Marianao
City:
Havana
País:
Cuba
Zip Code:
11500
Telephone:
+53-72601230
Email address:
carglez@infomed.sld.cu
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Not applicable
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Suspended
Date of first enrollment:
04/05/2020
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Pharmacodynamics and safety in healthy volunteers
Health condition(s) code:
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Healthy Volunteers
Health condition keyword:
pharmacodynamics
Intervention(s):
Group I: Recombinant human interferon (IFN) alpha-2b, 1 drop (0.05 mL) in each nostril (0.5 MIU IFN alpha 2b), every 12 hours (2.0 MIU daily) for 5 consecutive days. Group II: Recombinant human interferon (IFN) alpha-2b, 3 drops (0.15 mL) sublingually (1.5 MIU IFN alpha 2b), every 12 hours (3.0 MIU daily) for 5 consecutive days. Group III: Recombinant human interferon (IFN) alpha-2b, 1 drop (0.05 mL) in each nostril (0.5 MIU IFN alpha 2b), every 6 hours (4.0 MIU daily) for 5 consecutive days. Group IV: Recombinant human interferon (IFN) alpha-2b, 5 drops (0.25 mL) sublingually (2.5 MIU IFN alpha 2b), every 12 hours (5.0 MIU daily) for 5 consecutive days. Group V: Recombinant human interferon (IFN) alpha-2b, 2 drops (0.1 mL) in each nostril (1.0 MIU IFN alpha 2b), every 8 hours (6.0 MIU daily) for 5 consecutive days. Group VI: Recombinant human interferon (IFN) alpha-2b, 12 drops (0.6 mL) diluted in 2 mL of water for injection, aerosolized (6.0 MIU IFN alpha 2b), every 12 hours (12.0 MIU daily) for 5 consecutive days.
Intervention code:
Interferon alpha-2
Interferon-alpha
Interferons
Administration, Sublingual
Administration, Intranasal
Nasal Sprays
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Levels of local and systemic expression of markers of activity of the cellular signaling system stimulated by IFN alpha (2-5 oligo adenylate synthetase for antiviral activity and β2-microglobulin for activity of the immune system), evaluated by PCR on tissue obtained from nasal scraping and sublingual (for evaluations at the local level) and in peripheral blood (for evaluations at the systemic level). Measurement time: At baseline, 72 hours after the first administration of IFN alfa and, 24 hours after the last administration.
Key secondary outcomes:
1) Levels of local and systematic expression of other pharmacodynamic markers (STAT-1 and STAT-3 as markers of stimulation of IFNs signaling and expression of Toll-like receptors 3 and 7 as markers of activation of the immune system) nasal scraping and sublingual. Measurement time: At baseline, 72 hours after the first administration of IFN alfa and, 24 hours after the last administration. 2) Levels of blood expression of NK cells, lymphocytes, activation of macrophages and HLD-DR (by flow cytometry). Measurement time: At baseline and, 24 hours after the last administration. 3) Clinical Adverse Events-A (They will be measured as: -AE occurrence (Yes, No), -AE description (name of the event), -AE intensity (mild, moderate, severe), -Causal relationship (unrelated, doubtful, possible, probable, Definitive), -Measures taken (None, Administration of any pharmacological therapy, Addition of a non-pharmacological therapy, Exit of the study, Hospitalization / prolongation of hospitalization), -Result (Fully resolved, Resolved with sequelae, Conditions in improvement, Present condition and unchanged, worsening, death caused by this event)). Measurement time: daily throughout five days.
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male
Minimum age:
19 years
Maximum age:
60 years
Inclusion criteria:
1) Apparently healthy male individuals. 2) Between 19 and 60 years old, both inclusive. 3) Absence of clinically relevant manifestations in the interrogation and physical examination. 4) Normal electrocardiogram. 5) Analysis of hematology, blood chemistry and urine within normal limits. 6) Normal body weight for height. 7) Voluntary nature of the subject by signing the informed consent.
Exclusion criteria:
1) Treatment with immunosuppressants in the last month prior to inclusion. 2) Ongoing systemic treatment, for any cause, with IFN alpha. 3) Malignant neoplasm (except basal skin carcinoma). 4) Acute respiratory disease of the respiratory tract in the preceding week or at the time of evaluation for inclusion. 5) Use of any other intranasal medication 6) Allergic rhinitis present or history of recurrent episodes. 7) Nasal bleeding present or history of recurrent episodes. 8) Chronic asthma. 9) Autoimmune disease. 10) History of endocrine-metabolic disorders. 11) History of significant acute diseases in the last 30 days. 12) History of chronic diseases (cardiovascular, respiratory, neurological, renal, gastrointestinal, hepatic or hematological). 13) Administration of an investigational drug in the 45 days prior to inclusion in the study. 14) Use of any medication during the 15 days before entering the study. 15) History of serious adverse reactions or hypersensitivity to any drug. 16) History of alcoholism or alcohol consumption within 24 hours prior to administration of the study drug. 17) Known hypersensitivity to any of the components of the formulation under study. 18) Obvious mental incapacity to issue consent and act accordingly with the study.
Type of population:
Adults
Type of participant:
Healthy volunteers
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Other
Other purpose:
Pharmacodynamics / Security
Allocation:
Randomized trial
Masking:
Open
Control group:
Uncontrolled
Study design:
Parallel
Phase:
1
Target sample size:
30
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Hugo
Last Name:
Nodarse Cuni
Specialty:
Doctor of Pharmaceutical Sciences
Affiliation:
Center for Genetic Engineering and Biotechnology (CIGB).
Postal Address:
Ave. 31 entre 158 y 190, Cubanacan, Playa.
City:
Havana
País:
Cuba
Zip Code:
11300
Telephone:
+53-72085887, 72087465
Email :
hugo.nodarse@cigb.edu.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Hugo
Last Name:
Nodarse Cuni
Specialty:
Doctor of Pharmaceutical Sciences
Affiliation:
Center for Genetic Engineering and Biotechnology (CIGB).
Postal Address:
Ave. 31 entre 158 y 190, Cubanacan, Playa.
City:
Havana
País:
Cuba
Zip Code:
11300
Telephone:
+53-72085887, 72087465
Email :
hugo.nodarse@cigb.edu.cu
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
National Toxicology Center (CENATOX)
Status of evaluation:
Approved
Status of evaluation date of Ethic Committee:
27/04/2020
Postal address of Ethic Committee :
Calle 114 y Ave. 31, Marianao, La Habana, C.P:11500, Cuba
Telephone:
53-72601230
Correo electrónico:
carglez@infomed.sld.cu
About study completion
Section to complete the data related to the study completion.
Study completion date:
09/06/2020
Date of available results:
31/08/2020
Date of first publication:
30/09/2020
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000308
Date of Registration in Primary Registry:
03/05/2020
Record Verification Date:
2023/02/28
Next update date:
2024/02/28
Link to the spanish version:
Click here
Acerca del RPCEC
Estructura y Gobernanza
Política
Publicaciones
Reconocimientos
Comunicaciones
Noticias
Recursos útiles
Fundamentos del registro
Bibliografías en ensayos clínicos
Regulaciones cubanas
Otros registros
Plataforma Internacional de Registros de Ensayos Clínicos